Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Update: Juno’s CAR-T Clinical Trial To Resume After FDA Rescinds Clinical Hold

XTALKS VITALS NEWS

FDA

Juno has revised the treatment protocol for the study – named “ROCKET” – to stop using the chemotherapy drug, fludarabine, which was implicated in the patient deaths.

Tweetables from this article:

Tweet: #FDA has lifted the clinical hold on study of Juno Therapeutics’ CAR-T therapy http://ctt.ec/_4XQC+FDA has lifted the clinical hold on study of Juno Therapeutics’ CAR-T therapy.

Tweet: Juno will now exclusively use the cancer drug, cyclophosphamide, before CAR-T http://ctt.ec/cL6r7+Juno will now exclusively use the cancer drug, cyclophosphamide, before CAR-T.

Share this!

July 14, 2016 | by Sarah Massey, M.Sc.

The US Food and Drug Administration (FDA) has lifted the clinical hold on a study of Juno Therapeutics’ lead CAR-T therapy, which will allow the biotech company to resume enrollment. The Phase II clinical trial was put on hold last week following the deaths of three patients receiving the immunotherapy.

Juno has revised the treatment protocol for the study – named “ROCKET” – to stop using the chemotherapy drug, fludarabine, which was implicated in the patient deaths. To pre-condition patients before they receive the CAR-T cell therapy, the study investigators will now exclusively use the cancer drug, cyclophosphamide.

Alongside Kite Pharma and Novartis, Juno has been a leader in the promising CAR-T therapy space. After three patients died following treatment with the company’s lead candidate – known as JCAR015 – many raised concerns about the cancer treatment’s safety.

JCAR015 was designed to treat patients with relapsed or refractory B cell acute lymphoblastic leukemia. The FDA’s clinical hold on the study was expected to be a major roadblock delaying, or even preventing, further development of JCAR015.

As Juno was quick to identify fludarabine as the likely culprit in the patient deaths, the FDA has given the company the go-ahead to continuing enrolling more patients in the clinical trial. Despite the quick turn-around, the delay could still affect Juno’s plans to apply for FDA approval in 2017.

“Our view is not that this toxicity was caused exclusively by this second chemotherapy called fludarabine that we added,” said Juno CEO Hans Bishop, on CNBC. “It is a combination of the strength of the chemotherapy we used with the cells.”



Last week, Juno submitted revised copies of its consent form, investigator brochure and trial protocol to the FDA, complying with the regulator’s request for this information. While the FDA has approved Juno’s request to continue with the ROCKET clinical trial, it’s still not certain how fludarabine – in combination with the CAR-T immunotherapy – led to the death of the three patients.

Juno conducted a previous CAR-T clinical trial using cyclophosphamide alone, and received positive results from that study. According to Bishop, JCAR015 still has the potential to be an effective treatment for patients with relapsed or refractory B cell acute lymphoblastic leukemia.

“Losing patients on a clinical trial is always more than a blip in the road. It is a sobering experience,” continued Bishop. “We are clearly figuring out how to best use these potent therapies. The promise of them, I think remains unchanged.”


Keywords: CAR-T, FDA, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.